2020
DOI: 10.1007/s00277-020-04130-2
|View full text |Cite
|
Sign up to set email alerts
|

Recurrence of immune thrombocytopenia at the time of SARS-CoV-2 infection

Abstract: Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Fig. 1 Timeline of platelet count after treatment of secondary (systemic lupus erythematosus-related) ITP recurrence in a 37-year-old female patient with COVID-19 infection. IVIG, intra-venous immune globulins; IVMP, intra-venous methyl-prednisolone; PDN, prednisone

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
16
0
2

Year Published

2020
2020
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 18 publications
(18 citation statements)
references
References 6 publications
0
16
0
2
Order By: Relevance
“…Flares of previously diagnosed ITP have been described, as in the case of a woman with a previous diagnosis of ITP, receiving immunosuppressive therapy with prednisone (10 mg/daily) and cyclosporine (50 mg/daily) experiencing a severe exacerbation with marked decrease of platelet count during COVID-19 [ 28 ]. Another case concerned a 37-year-old woman who was treated with mycophenolate mofetil for ITP secondary to systemic lupus erythematosus and had a flare during mild COVID-19 [ 29 ]. ITP exacerbation also occurred in a 34-year-old woman during the second trimester of pregnancy [ 30 ] and a de novo disease was diagnosed in another pregnant woman [ 31 ].…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Flares of previously diagnosed ITP have been described, as in the case of a woman with a previous diagnosis of ITP, receiving immunosuppressive therapy with prednisone (10 mg/daily) and cyclosporine (50 mg/daily) experiencing a severe exacerbation with marked decrease of platelet count during COVID-19 [ 28 ]. Another case concerned a 37-year-old woman who was treated with mycophenolate mofetil for ITP secondary to systemic lupus erythematosus and had a flare during mild COVID-19 [ 29 ]. ITP exacerbation also occurred in a 34-year-old woman during the second trimester of pregnancy [ 30 ] and a de novo disease was diagnosed in another pregnant woman [ 31 ].…”
Section: Resultsmentioning
confidence: 99%
“…Patients affected by autoimmune diseases are reasoned to be generally more susceptible to infections, due to the use of the immunosuppressive treatments and particularly when the disease status is not fully under control [ 91 ]. In some cases, in fact, these patients can develop disease flares or new autoimmune complications in the context of SARS-CoV-2 infection, as described for patients with pre-existing hemolytic anemia [ 12 ], ITP [ 29 , 30 ], and arthritis [ 71 ]. It is to be noted that diverse outcomes of SARS-CoV-2 infection in patients with existing autoimmune disease appear in the literature.…”
Section: Discussionmentioning
confidence: 99%
“…To the best of our knowledge, this is the first comprehensive systematic review of new-onset ITP secondary to COVID-19, comprising 45 cases described in literature until date. We excluded 3 patients with COVID-19 from analysis, who had presented with exacerbation of previously diagnosed chronic or persistent ITP [30][31][32]. Likewise, we excluded one patient who contracted SARS-CoV-2 in post-partum period 3 weeks after being diagnosed with Evans syndrome and treated with rituximab infusion due to poor response to steroids [33].…”
Section: Discussionmentioning
confidence: 99%
“…Thrombocytopenia might also result from immunological peripheral destruction of platelets, as demonstrated in viral infections including HIV and HCV [14]. Cases of immune thrombocytopenic purpura associated with SARS-CoV-2 infection have recently been reported, both recurrence of chronic immune thrombocytopenic purpura [15,16] or newly diagnosed, both adult or pediatric [17][18][19][20][21][22][23][24][25][26][27]. Recommendations have recently been issued to help the management of immune thrombocytopenia during the COVID-19 pandemic [28].…”
Section: Discussionmentioning
confidence: 99%